Investors & Media

Transformative science, targeted medicines

We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.

SEC Filings

SEC Filings

Filing date	Form	Description	View
Apr 20, 2015	S-1/A	Amended Registration statement for face-amount certificate companies	View HTML 0001047469-15-003668.pdf 0001047469-15-003668.rtf 0001047469-15-003668.xls
Apr 27, 2015	8-A12B	Registration of certain classes of securities 12(b) of the Securities Exchange Act	View HTML 0001104659-15-030565.pdf 0001104659-15-030565.rtf 0001104659-15-030565.xls
Apr 27, 2015	CORRESP	CORRESP	View HTML 0001104659-15-030559.pdf 0001104659-15-030559.rtf 0001104659-15-030559.xls
Apr 27, 2015	CORRESP	CORRESP	View HTML 0001104659-15-030564.pdf 0001104659-15-030564.rtf 0001104659-15-030564.xls
Apr 29, 2015	CERTNAS	CERTNAS	View HTML 9999999997-15-008888.pdf 9999999997-15-008888.rtf
Apr 29, 2015	S-1MEF	Registration of up to an additional 20% of securities for any offering registered on an S-1	View HTML 0001104659-15-031752.pdf 0001104659-15-031752.rtf 0001104659-15-031752.xls
Apr 29, 2015	3	Initial filing by director officer or owner of more than ten percent.	View HTML 0001012975-15-000312.pdf 0001012975-15-000312.rtf 0001012975-15-000312.xls
Apr 29, 2015	3	Initial filing by director officer or owner of more than ten percent.	View HTML 0000315066-15-002587.pdf 0000315066-15-002587.rtf 0000315066-15-002587.xls
Apr 29, 2015	EFFECT	EFFECT	View HTML 9999999995-15-001054.pdf 9999999995-15-001054.rtf 9999999995-15-001054.xls
Apr 30, 2015	3	Initial filing by director officer or owner of more than ten percent.	View HTML 0001104659-15-031949.pdf 0001104659-15-031949.rtf 0001104659-15-031949.xls

Continue